The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair. (Q39820505)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633683%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

title

The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633683%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

0 references

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633683%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Mike-Andrew Westhoff

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633683%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Adriana Eramo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633683%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Klaus-Michael Debatin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633683%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

J A Kandenwein

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633683%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

S Karl

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633683%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

S H K Vellanki

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633683%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

V Braun

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633683%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

G Antoniadis

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633683%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

language of work or name

English

0 references

publication date

27 July 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633683%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633683%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633683%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633683%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

3586-3596

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19633683%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/onc.2009.215

3 February 2020

exact match

0 references

cites work

Focusing on foci: H2AX and the recruitment of DNA-damage response factors

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Cancer stem cells and chemoradiation resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

PI3K/PTEN signaling in tumorigenesis and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Antitumour imidazotetrazines--XI: Effect of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one [CCRG 81045; M and B 39831 NSC 362856] on poly(ADP-ribose) metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

The in vivo comet assay: use and status in genotoxicity testing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Novel therapies for malignant gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Mechanisms of human DNA repair: an update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Molecular predictors in glioblastoma: toward personalized therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Chemotherapy resistance of glioblastoma stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

31 March 2020

Phosphoinositide kinases

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Pegylated liposomal doxorubicin in recurrent malignant glioma: analysis of a case series

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Defining the role of mTOR in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Sensing and repairing DNA double-strand breaks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

PIKK-ing a new partner: a new role for PKB in the DNA damage response.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

PI3K inhibitors for cancer treatment: where do we stand?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

31 March 2020

Glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Genetic pathways to glioblastoma: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Activation of Akt predicts poor outcome in neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

An integrated genomic analysis of human glioblastoma multiforme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

A mechanism for DNA-PK activation requiring unique contributions from each strand of a DNA terminus and implications for microhomology-mediated nonhomologous DNA end joining

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

The multifaceted role of mTOR in cellular stress responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Changing paradigms--an update on the multidisciplinary management of malignant glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Non-homologous end joining, but not homologous recombination, enables survival for cells exposed to a histone deacetylase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

DNA end-independent activation of DNA-PK mediated via association with the DNA-binding protein C1D

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215

PI3K pathway alterations in cancer: variations on a theme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.215